Bioequivalence and Bioavailability Forum 09:02 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

NTI Criteria Wavier [Study As­sess­ment]

posted by sury - India, 2018-12-24 07:04  - Posting: # 19711
Views: 209

(edited by mittyri on 2018-12-24 11:21)

Hi Forum Members,

Hope all are doing well...

As per USFDA NTI Criteria, the drug has to pass the full NTI Criteria i.e., Average Equivalence, 95% Upper bound criteria and Within test vs Reference 90% CI Upper limit should be less than 2.5

Coming to my drug here, it has been recently set to NTI criteria

As per the Draft guidance we have conducted Full replicate design and now we got to know to know that study has lost his NTI Criteria i.e., 95% upper bound.

But if i see the T/R Ratios were better than that of the marketed drug and we are confident about it

is there any way to justify that and get a wavier from NTI Criteria..?


Thanks and Regards,
Sury


Edit: Category changed; see also this post #1[Mittyri]

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,016 posts in 4,056 threads, 1,297 registered users;
online 7 (0 registered, 7 guests [including 6 identified bots]).

The only people who see the whole picture are the ones
who step out of the frame.    Salman Rushdie

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed